Technical + Potential Catalyst. Low risk high reward
Updated
Broke out of a trend line and retested 1.30, looks to be heading towards 1.80 based on the sideways pattern. If it breaks out of sideways pattern there may be more upside.
Stop loss can be somewhere below the sideways pattern.
Kintara will be presenting in H.C. Wainwright Bioconnect 2021 Virtual Conference on January 11 – January 14, 2021.
I am expecting them to receive positive exposure through presentation of their various positive topline data from phase 2 trials, providing more specifics and announcement of first patient enrolment into their phase 3 Glioblastoma Multiforme (GBM) trial.
- VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory GBM and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.
- Glioblastoma Multiforme is the most common and lethal form of brain cancer.
- VAL-083 has been assessed in 42 Phase 1 and Phase 2 clinical trials sponsored by the U.S. National Cancer Institute ("NCI") as a treatment against various cancers.
- VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia ("CML") and lung cancer.
Stop loss can be somewhere below the sideways pattern.
Kintara will be presenting in H.C. Wainwright Bioconnect 2021 Virtual Conference on January 11 – January 14, 2021.
I am expecting them to receive positive exposure through presentation of their various positive topline data from phase 2 trials, providing more specifics and announcement of first patient enrolment into their phase 3 Glioblastoma Multiforme (GBM) trial.
- VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory GBM and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.
- Glioblastoma Multiforme is the most common and lethal form of brain cancer.
- VAL-083 has been assessed in 42 Phase 1 and Phase 2 clinical trials sponsored by the U.S. National Cancer Institute ("NCI") as a treatment against various cancers.
- VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia ("CML") and lung cancer.
Note
Price target 1.80 reached. Also broke out of the sideways pattern so can take some profit and hold remaining position. Should continue to rise
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.